Decoy Therapeutics Inc. (DCOY)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.13
- As of
Kresmion compiles this page from DCOY's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Decoy Therapeutics Inc. (DCOY): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-23.
See the full DCOY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for DCOY on one page. Preview it with sample data, then open it live with a free account.
Preview the DCOY dossierActive events for DCOY
- mediumEarnings above estimates
Q3-2023: Beat consensus by 46.9% - EPS $-936 vs $-1762.56 estimate
- mediumEarnings above estimates
Q1-2024: Beat consensus by 94.0% - EPS $-590.4 vs $-9840.96 estimate
- mediumEarnings above estimates
Q3-2024: Beat consensus by 69.0% - EPS $-136.8 vs $-440.64 estimate
- mediumEarnings below estimates
Q2-2023: Missed consensus by 8.1% - EPS $-2059.2 vs $-1904.5489 estimate
- mediumEarnings above estimates
Beat consensus by 46.9% - EPS $-936 vs $-1762.56 estimate
FREE, NO ACCOUNT
Every event on DCOY, as it fires
You are seeing 5 of 7 events recorded on DCOY since 2026-05-29.
The five above landed across 2 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, DCOY
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
DCOY's 10-Q filed Aug 12, 2026 states:
The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on DCOY
DCOY against its peers
DCOY's return on equity of -212.6% ranks in the 50th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-03-31.
| Metric | DCOY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 101551 | n/a | 10 |
| Gross margin | n/a | 63.1% | n/a | 8 |
| Operating margin | n/a | -2190.0% | n/a | 9 |
| Net margin | n/a | -2419.9% | n/a | 9 |
| Return on equity | -212.6% | -181.0% | 50 | 14 |
Peers (19): LSBCF.D, CLDI, VIVS, CMND, JUNS, SILO, MBIO, APVO, ACUT, KALA, REVB, HCWB, VSBC, CASIF, SLXN, ONCO, SXTP, EOCN, ERNA. Left out: VCNX (period gap), BIXT (no annual filing), GPLL (period gap), NYMXF (period gap), AGNPF (no annual filing), NRSN (no annual filing). Fiscal periods ending between 2025-03-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (DCOY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in DCOY on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on DCOY in the last 180 days.
Upstream: SEC EDGAR filings for DCOY
Kresmion, "Decoy Therapeutics Inc. (DCOY) institutional holdings and SEC filings", data as of 2026-09-23, https://kresmion.com/research/DCOY. Upstream data: SEC EDGAR filings for DCOY.
Link to this data (HTML):
<a href="https://kresmion.com/research/DCOY">Decoy Therapeutics Inc. (DCOY) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow DCOY on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to DCOY for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.